Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

Inclusion Criteria: * ≥18 years and ≤75 years in age * Patients with relapsed or refractory AML * No more than one prior stem cell transplant * Has not received the chemotherapy regimen to be used for induction on this trial * Is considered medically eligible to receive the chemotherapy regimen to be used for induction on this trial Exclusion Criteria: * Patients with acute promyelocytic leukemia, acute leukemia of ambiguous lineage (biphenotypic leukemia), chronic myeloid leukemia with myeloid blast crisis, or secondary refractory AML. * Active signs or symptoms of CNS involvement by malignancy. * Stem cell transplantation ≤4 months prior to dosing. * Any immunotherapy or radiotherapy therapy within 28 days of dosing; any other experimental therapy or chemotherapy within 14 days of dosing. * Prior use of G-CSF, CM-CSF or plerixafor within 7 days of dosing. * Inadequate organ function. * Abnormal liver function. * Known active infection with hepatitis A, B, or C, or human immunodeficiency virus. * Moderate kidney dysfunction (glomerular filtration rate \<45 mL/min). * Uncontrolled acute life-threatening bacterial, viral, or fungal infection. * Clinically significant cardiovascular disease. * Major surgery within 4 weeks of dosing.

Reproduced word-for-word from the public registry record — the study team can answer questions about it.